Biocon forays into China, signs pact with CMS to sell 3 generic products

According to data, the total market size for these three generic products in China is about $0.8 billion

India’s largest bio-pharmaceutical major Biocon has entered a licence and supply pact with a subsidiary of China Medical System (CMS) for three generic formulation products in China. With this, the company gets access to the second biggest pharma market in the world.  

As part of the agreement, Biocon will be responsible for the development, manufacturing and supply of the products, while CMS will be responsible for registration and commercialisation of the products in the neighbouring country. The company, however, did not name the three products which are a part of this deal.

Arun Chandavarkar, CEO and Joint Managing Director of